Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2018

View Archived Issues

Taisho presents safety and PK data for TS-134

Astatine-211 targeted to CD38 tested in minimal residual disease multiple myeloma models

First-in-human data for JNJ-54175446 published

Phase II results for the dissociative steroidal anti-inflammatory drug vamorolone in DMD

G0S2 is epigenetically silenced in IDH1-mutant glioma, leading to improved prognosis

Amgen develops anti-GIPR antibody

Immune cells can cause pain for brain

Inducing senescence sets off antitumor response

Innate immunity shuttles antigens to B-cell centers

Novel pyrrolopyridine analogues show human CMV-inhibitory activity by unusual mechanism of action

Novel SIRT6 allosteric activator, MDL-800, suppresses tumor growth in xenograft models of HCC

Transcription factor suppresses immunity, halts lupus in mice

Emergent BioSolutions makes FDA submission for potential emergency use of NuThrax

InventisBio and Betta Pharma sign Chinese agreement for D-0316

University of Southern California patent describes agents for imaging ADP-ribosylation

Anti-RSV compounds reported in Enanta Pharmaceuticals patent

Bristol-Myers Squibb describes formyl peptide receptor agonists

PTC Therapeutics patents compounds for Huntington's disease

Tianjin Zhongxin Pharmaceutical Research Center reports agents for treatment of cancer

National Health Research Institutes reports development of tyrosine kinase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...